Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
10/28/2022* -- Results Q3 2022 -- 0.24 --
10/28/2022* 16:30 EST Earnings Call Q3 2022 -- -- --
07/28/2022 16:30 EST Earnings Call Q2 2022 -- -- --
07/28/2022 -- Results Q2 2022 0.17 0.19 -10.16%
04/28/2022 -- Results Q1 2022 0.08 0.13 -38.76%
04/28/2022 16:30 EST Earnings Call Q1 2022 -- -- --
02/10/2022 -- Results Q4 2021 0.17 0.21 -19.89%
02/10/2022 16:30 EST Earnings Call Q4 2021 -- -- --
*Estimated Date/Time

Earnings

Next Report Date 10/28/2022 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 07/28/2022
Beat/Miss Upgrade
Return Since 6.10%
Last FQE 06/30/2022
Next FQE 09/30/2022

Profile

Edit
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
URL https://www.dexcom.com
Investor Relations URL https://investors.dexcom.com
HQ State/Province California
Sector Healthcare
Industry Medical Devices
Equity Style Mid Cap/Growth
Next Earnings Release Oct. 28, 2022 (est.)
Last Earnings Release Jul. 28, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date --
Yield (TTM) 0.00%
Forward Yield --
Payout Ratio 0.00%
Cash Payout Ratio 0.00%
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
48.77%
-27.11%
-3.87%
108.7%
82.59%
69.02%
45.23%
-31.24%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-8.98%
-17.91%
-0.34%
83.12%
14.96%
115.8%
49.32%
4.08%
1.72%
3.26%
16.11%
72.64%
31.23%
23.43%
38.39%
31.76%
-33.69%
17.78%
45.98%
131.1%
-5.74%
33.24%
91.51%
22.98%
-56.45%
19.76%
35.65%
161.4%
-62.47%
110.4%
-32.67%
71.38%
27.13%
As of August 15, 2022.

Profile

Edit
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
URL https://www.dexcom.com
Investor Relations URL https://investors.dexcom.com
HQ State/Province California
Sector Healthcare
Industry Medical Devices
Equity Style Mid Cap/Growth
Next Earnings Release Oct. 28, 2022 (est.)
Last Earnings Release Jul. 28, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

Symbol Dollars Invested % Weight
TSNCX 152.26M USD 5.58%
DYN2718 86.74M USD 3.81%
IHI 214.73M USD 3.08%
WMGRX 159.93M USD 2.92%
RPG 51.24M USD 1.93%
BMEZ 44.33M USD 1.75%
NUGO 56.82M USD 1.73%
KAUBX 80.85M USD 1.60%
JMGQX 101.50M USD 1.45%
VMGIX 194.77M USD 1.08%
VOT 215.07M USD 1.07%
IWP 122.68M USD 0.93%

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Morningstar Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter DXCM Tweets